A randomized controlled trial conducted by researchers at the University of Surrey on November 13, 2026, and published in the European Heart Journal Open, investigated the effects of a multi-component anti-aging nutritional supplement named NOVOS Core. The study involved 61 participants, with 33 taking the supplement and 28 receiving a placebo once daily for six months to evaluate cardiovascular biomarkers. The researchers aimed to test the hypothesis that targeting multiple biological processes of aging simultaneously could yield measurable improvements in cardiovascular health, focusing on endothelial function, arterial stiffness, and systolic blood pressure as primary biomarkers. Key findings revealed that participants taking the supplement experienced improved flow-mediated dilation just 60 minutes after the first dose, along with reduced arterial stiffness and a 6.1 mmHg lower systolic blood pressure compared to the placebo group after six months of daily consumption. While these results demonstrate promising acute and medium-term biomarker improvements, experts emphasize that further larger-scale clinical trials are required to determine whether these vascular enhancements translate into long-term reductions in major cardiovascular disease events.
